Porownywarka

Liraglutide vs Tirzepatide side-by-side

Zestaw do czterech peptydów według statusu dowodów, mechanizmów, dawkowania z badań, skutków ubocznych i referencji.

Wybrane (2/4)

LiraglutideTirzepatide

Udostępnij porównanie peptydów

Wlasciwosc	Liraglutide	Tirzepatide
Kategoria	Redukcja masy	Redukcja masy
Znany tez jako	Victoza, Saxenda	Mounjaro, Zepbound, LY3298176
Zatwierdzony przez FDA	Tak	Tak
Status kliniczny	FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025. Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA	FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea Pre Przedkliniczne I Faza I II Faza II III Faza III IV Faza IV FDA Zatwierdzone przez FDA
Czego oczekiwac	Weight management, diabetes control, appetite suppression	Weight loss, diabetes management, metabolic health
Jak dziala	Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety.	Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.
Typowe dawkowanie	1.8-3 mg daily · Once daily · Subcutaneous injection daily	5-15 mg weekly (after titration) · Once weekly
Dawkowanie z badań	0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily	2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly
Typowy czas trwania	Long-term / chronic use	Long-term / chronic use
Podanie	Subcutaneous injection daily	Subcutaneous injection weekly
Timing	Morning or evening, consistent daily With or without food	Morning, same day each week With or without food
Poziom dowodów	Zatwierdzone przez FDA	Zatwierdzone przez FDA
Mozliwe skutki uboczne	Nausea (Common; source highlights gastrointestinal effects especially during dose escalation.) Vomiting (Reported gastrointestinal side effect.) Diarrhea (Reported gastrointestinal side effect.) +7 więcej Constipation (Reported side effect.) Headache (Reported side effect.) Hypoglycemia (Reported with insulin or sulfonylureas.) Pancreatitis (Reported serious adverse event.) Gallbladder disease (Reported serious adverse event.) Acute kidney injury (Reported serious adverse event.) Thyroid C-cell tumors (Boxed warning; source says this is based on rodent studies and that a clear human link has not been established.)	Nausea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.) Diarrhea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.) Vomiting (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) +9 więcej Constipation (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) Decreased appetite (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.) Abdominal pain (Listed in the source adverse-effect information.) Injection site reactions (Listed in the source adverse-effect information.) Hypoglycemia (with insulin/sulfonylureas) (The source specifically gives the insulin/sulfonylurea context.) Pancreatitis (Listed in the source adverse-effect information.) Gallbladder problems (Listed in the source adverse-effect information.) Acute kidney injury (Listed in the source adverse-effect information.) Thyroid C-cell tumors (The source labels this a BOXED WARNING and states a contraindication with MTC/MEN 2.)
Podsumowanie researchu	The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link.	The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.
Referencje	PubMed New England Journal of Medicine +2 więcej Drugs.com Pharmacy Times	Źródło Źródło +2 więcej Źródło Źródło
Pełny profil	Zobacz szczegóły	Zobacz szczegóły

Zapisz to porównanie

Trzymaj ten zestaw researchowy pod reka na darmowym koncie PeptiGuide.

Zapisz porównanie - darmowe konto

Trackuj swoja ścieżkę peptydówa

Zamien research w prywatny log protokołu, gdy będziesz gotowy.

Trackuj ścieżkę peptydówa

Wyłącznie edukacyjnie. Te informacje są agregowane z publicznych badań i raportów społeczności. To nie jest poradą medyczną, a informacje o dawkowaniu są opisowe, nie rekomendacyjne. Zawsze konsultuj się z wykwalifikowanym specjalistą ochrony zdrowia.

Wlasciwosc

Liraglutide

Tirzepatide

Kategoria

Redukcja masy

Znany tez jako

Victoza, Saxenda

Mounjaro, Zepbound, LY3298176

Zatwierdzony przez FDA

Tak

Status kliniczny

FDA approved for diabetes as Victoza and weight loss as Saxenda; source also reports Teva generic Saxenda launched Aug 2025.

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

FDA Approved - Type 2 diabetes (adults and pediatric 10+), chronic weight management, obstructive sleep apnea

Pre
Przedkliniczne
I
Faza I
II
Faza II
III
Faza III
IV
Faza IV
FDA
Zatwierdzone przez FDA

Czego oczekiwac

Weight management, diabetes control, appetite suppression

Weight loss, diabetes management, metabolic health

Jak dziala

Liraglutide is reported to act as a GLP-1 receptor agonist. The source describes glucose-dependent pancreatic insulin signaling, reduced glucagon activity, delayed gastric emptying, and central appetite-related GLP-1 receptor activity in the hypothalamus as mechanisms relevant to glucose control and satiety.

Tirzepatide is described as a dual agonist of GIP and GLP-1 receptors, two gut incretin signals associated with eating. In the source account, GLP-1 activity is linked to glucose-dependent insulin release, lower glucagon, delayed gastric emptying, and appetite reduction. GIP activity is described as potentially augmenting insulin response and energy handling in fat tissue, and the source says dual activity may outperform GLP-1-only activity. It also reports a fatty-acid chain that promotes albumin binding for weekly dosing, while noting that the added role of GIP is not fully resolved.

Typowe dawkowanie

1.8-3 mg daily · Once daily · Subcutaneous injection daily

5-15 mg weekly (after titration) · Once weekly

Dawkowanie z badań

0.6mg daily (starting) · Once daily · Long-term / chronic use · Subcutaneous injection daily

2.5mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly

Typowy czas trwania

Long-term / chronic use

Podanie

Subcutaneous injection daily

Subcutaneous injection weekly

Timing

Morning or evening, consistent daily

With or without food

Morning, same day each week

With or without food

Poziom dowodów

Zatwierdzone przez FDA

Mozliwe skutki uboczne

Nausea (Common; source highlights gastrointestinal effects especially during dose escalation.)
Vomiting (Reported gastrointestinal side effect.)
Diarrhea (Reported gastrointestinal side effect.)

+7 więcej

Constipation (Reported side effect.)
Headache (Reported side effect.)
Hypoglycemia (Reported with insulin or sulfonylureas.)
Pancreatitis (Reported serious adverse event.)
Gallbladder disease (Reported serious adverse event.)
Acute kidney injury (Reported serious adverse event.)
Thyroid C-cell tumors (Boxed warning; source says this is based on rodent studies and that a clear human link has not been established.)

Nausea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.)
Diarrhea (Reported by the source; it describes gastrointestinal effects as commonly more prominent during titration.)
Vomiting (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)

+9 więcej

Constipation (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)
Decreased appetite (Reported by the source; individual experience is stated to vary with dose, duration, and health factors.)
Abdominal pain (Listed in the source adverse-effect information.)
Injection site reactions (Listed in the source adverse-effect information.)
Hypoglycemia (with insulin/sulfonylureas) (The source specifically gives the insulin/sulfonylurea context.)
Pancreatitis (Listed in the source adverse-effect information.)
Gallbladder problems (Listed in the source adverse-effect information.)
Acute kidney injury (Listed in the source adverse-effect information.)
Thyroid C-cell tumors (The source labels this a BOXED WARNING and states a contraindication with MTC/MEN 2.)

Podsumowanie researchu

The source characterizes liraglutide evidence as human clinical evidence rather than preliminary research. It reports that the LEADER trial enrolled 9,340 high-risk participants with type 2 diabetes and found cardiovascular death, heart attack, or stroke occurred in 13.0% with liraglutide versus 14.9% with placebo, published in the New England Journal of Medicine in 2016. For weight outcomes, the source cites the SCALE program, where adults without diabetes lost about 8% of body weight at 56 weeks on the 3.0 mg Saxenda dose. It also notes that nausea, vomiting, and diarrhea are common, particularly during dose escalation, and that labeling includes a boxed warning for thyroid C-cell tumors based on rodent findings without a confirmed human link.

The source reports that SURMOUNT-1, published in the New England Journal of Medicine in 2022, involved adults with obesity without diabetes. It describes average body-weight change of 22.5 % with 15 mg over 72 weeks (a 72 week duration) versus 2.4 % with placebo, and says about 9 in 10 participants lost weight. For SURMOUNT-5 (2025), the source reports roughly 20 % weight loss for tirzepatide compared with about 14 % for semaglutide. It further describes HbA1c reductions in the SURPASS diabetes program and says a large cardiovascular outcomes trial supported its safety profile. The source characterizes the cited trials as large, randomized, and peer-reviewed; the listed references should be reviewed for methods and results.

Referencje

PubMed New England Journal of Medicine

+2 więcej

Drugs.com Pharmacy Times

Źródło Źródło

+2 więcej

Źródło Źródło

Pełny profil

Zobacz szczegóły